The Anti-myocardial Fibrosis Effect of Vericiguat in HFrEF
Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
Vericiguat is a new medication therapy choice for the patients with heart failure with
reduced ejection fraction (HFrEF), in the latest trial, it met the expectation to reduce
incidence of death from cardiovascular causes or hospitalization for heart failure among
HFrEF patients. Myocardial fibrosis as a pathological change in heart failure, it contributes
to left ventricular dysfunction leading to development of the disease, experimental studies
have showed the potential prevention, or even reversal effect of sGC stimulators in left
ventricular hypertrophy and fibrosis. Our study is a prospective controlled clinical trial
aim to verify the anti-myocardial fibrosis effect of vericiguat in heart failure with reduced
ejection fraction.